Adicet Bio, Inc.
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
ACET | NDAQ
Overview
Corporate Details
- ISIN(s):
- US0070021086
- LEI:
- Country:
- United States of America
- Address:
- 131 DARTMOUTH STREET, 2116 BOSTON
- Website:
- https://www.adicetbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies. The company is advancing a pipeline of first-in-class, 'off-the-shelf' T cell product candidates for the treatment of cancer and autoimmune diseases. Adicet's proprietary platform leverages the unique properties of gamma delta T cells to engineer therapies with novel targeting mechanisms and the potential for best-in-class drug exposure. These treatments are designed to be readily available 'on-demand,' aiming to establish a new generation of immune cell therapy for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adicet Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adicet Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adicet Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
